NEW YORK, Oct. 12 – Shares in Cepheid skyrocketed nearly 50 percent during mid-day trading on Friday after reports surfaced that an employee of NBC in New York was diagnosed with anthrax.

As of 2:00 p.m. EST, shares in the company, which makes and sells technology that performs genetic testing, were trading up more than 48 percent at $8.10 on the Nasdaq but eased a bit one hour later.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.